Therefore, the enrichment of the TGF-β signaling pathway in CTCs during Atezo+Bev treatment in the non-responder group in this study may indicate that activation of TGF-β signaling in primary HCC contributes to ICI resistance through immune exhaustion and increased CTC numbers by promoting EMT. Here, TGFB1 is linked to hepatocellular carcinoma.